What changed
$VKTX — BUY 📊
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
🎯 Q1 FY26 | EPS $-1.37 vs $-0.91 🔴
💡 Consensus sees VK2735 as a weak competitor in the crowded obesity space, focusing on cash burn and trial expense miss. Variant view: Phase 2 data supports potent weight loss with good tolerability, and obesity market size allows multiple winners.
📉 Reward/Risk: 2.0:1
🏢 Business Quality: 4/10 - Single-asset clinical biotech with no revenue, high cash burn, and competitive obesity landscape, but targeting a massive market.
📊 Valuation: fair — Using reverse DCF (prob.-adjusted peak sales of $3-5B implies ~$3B market cap is reasonable), peer comps (similar Phase 3 obesity plays trade...
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/VKTX0621
Why it matters
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.